Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer

Trial Title: Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer

NCT ID: NCT05949983

Condition: Breast Neoplasm

Conditions: Official terms:
Breast Neoplasms

Conditions: Keywords:
Physical Activity
Exercise
Exercise Therapy
Breast Neoplasms
Medical costs
Healthcare Costs

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Other

Masking: None (Open Label)

Intervention:

Intervention type: Other
Intervention name: APA Program
Description: Patients treated and monitored for their breast cancer following the 6-month APA program.
Arm group label: APA program Group

Intervention type: Other
Intervention name: Recommendations for physical activity
Description: Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
Arm group label: Physical activity recommendation Group

Summary: Adapted physical activity (APA) was recognized as a non-drug therapy by the French Health Authority (HAS) in 2011. Very few studies have examined the efficiency of APA programs during the active phase of treatment in cancer patients. The investigators assumed that non-drug therapy such as APA could improve the quality of life and reduces health costs. The main objective of this study is to assess the efficiency of a standardized APA program, as compared to conventional management including simple recommendations for the practice of physical activity in women in phase active breast cancer treatment.

Detailed description: Scientific rationale: The incidence of breast cancer in women is on the rise again over the period 2010-2018. The overall cost of cancer treatment is 16.8 billion euros, including 3.6 billion for drugs alone. The treatments are more and more prolonged, the proportion of anticancer drugs continues to increase with 10% of the amount reimbursed for drugs delivered in pharmacies in 2017. Adapted physical activity (APA) was recognized as a non-drug therapy by the HAS in 2011. It reduces certain side effects of treatments, as well as certain symptoms linked to the catabolic activity of the disease such as: fat gain, loss of muscle mass, physical deconditioning, fatigue or pain. For breast cancer, a meta-analysis showed that APA following adjuvant therapy may have a beneficial effect on quality of life. The APA shows in particular for breast cancer, a reduction in all-cause mortality as well as specific mortality and a reduction in recurrence.The prescription of APA has been allowed since the 2016 health law but there is no coverage by the French national health insurance fund (CNAM) despite the benefits shown. APA is only accessible in a few centers in France that have chosen to offer it to patients, thus creating social inequalities in health. Very few studies have examined the efficiency of APA programs during the active phase of treatment. They related to cohorts of 60 to 165 patients and uses different methods. The investigators decided to set up a study that can measure the efficiency of the standardized APA programs offered to patients diagnosed with breast cancer, assuming that non-drug therapy such as APA would improve the quality of life while reducing health costs. Description of the procedures: The intervention consists of an initial consultation appointment with a medical check-up and physical tests, then inclusion in the standardized APA program for 6 months. The control group will be offered the same initial consultation appointment with medical check-up and physical tests and will receive recommendations for physical practice as well as a calendar of activities to be practiced independently for 6 months. Inclusion in the APA program will be offered one year after inclusion. Follow-up: The data will be collected at T0, T + 3 months, T + 6 months, T + 9 months and T + 12 months in both arms. There will be 1 year of data analysis.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - women with breast cancer - any type of breast cancer, all grades, all stages - during treatment: surgery +/- chemotherapy +/- radiotherapy +/- hormone therapy Exclusion Criteria: - World Health Organization (WHO) 4 - Unstable angina - Uncontrolled Atrial fibrillation - Uncontrolled high blood pressure - Recent myocardial infarction or myocarditis or pericarditis or thromboembolic disease (less than 3 weeks) - Aortic stenosis or valve disease to operate - Cardiac or respiratory failure, with dyspnea at rest - Symptomatic anemia, thrombocytopenia - Lytic or painful bone metastases, Severe osteoporosis - Severe infectious syndrome, - Surgery in the last 3 weeks - Extreme fatigue, sharp pain, dizziness, disturbance of consciousness, severe undernutrition - Contraindication to the practice of an adapted physical activity programme - Currently involved or exclusion period of a interventional study or adapted Physical Activity program - Patient with protective measures (guardianship, curators, and deprivation of liberty). - Pregnancy or breastfeeding - Patient with severe functional limitations

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Marie-Eve Rougé-Bugat

Address:
City: Toulouse
Country: France

Contact:
Last name: Marie-Eve Rougé-Bugat, MD

Phone: 561800123

Phone ext: +33
Email: marieeve.rouge-bugat@dumg-toulouse.fr

Investigator:
Last name: Marie-Eve Rougé Bugat
Email: Principal Investigator

Start date: October 1, 2024

Completion date: October 1, 2026

Lead sponsor:
Agency: University Hospital, Toulouse
Agency class: Other

Source: University Hospital, Toulouse

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05949983